NEOT Neothetics, Inc.

1.37
0  -4%
Previous Close 1.43
Open 1.45
Price To book 1.44
Market Cap 18.94M
Shares 13,828,000
Volume 115,391
Short Ratio 1.25
Av. Daily Volume 135,498

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 endpoints not met December 2015. Phase 2 trial initiated December 23, 2016 with data due June 2017.
LIPO-202
Reduction of localized fat deposits under the chin (submental fat)
Phase 2 trial planned pending data from submental trial.
LIPO-202
Reduction of central abdominal bulging

Latest News

  1. Neothetics reports 4Q loss
  2. Neothetics reports 4Q loss
  3. NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  4. Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results
  5. Q4 2016 Neothetics Inc Earnings Release - Before Market Open
  6. Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
  7. Neothetics to Provide a Business Update and Release Fourth Quarter 2016 Financial Results Thursday, March 23, 2017
  8. NEOTHETICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  9. NEOTHETICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
  10. Neothetics (NEOT) Begins Phase II Study on Lead Candidate
  11. Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
  12. Neothetics Initiates Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
  13. NEOTHETICS, INC. Financials
  14. Neothetics Provides Business Update and Reports Third Quarter 2016 Financial Results
  15. NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  16. Neothetics to Provide a Business Update and Release Third Quarter 2016 Financial Results Thursday, November 10, 2016
  17. NEOTHETICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement
  18. Neothetics Provides Business Update and Reports Second Quarter 2016 Financial Results
  19. NEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
  20. Neothetics to Provide a Business Update and Release Second Quarter 2016 Financial Results Thursday, August 11, 2016